These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23333902)

  • 21. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.
    Benbassat CA; Maki KC; Unterman TG
    J Clin Endocrinol Metab; 1997 May; 82(5):1484-91. PubMed ID: 9141538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
    Black RN; Ennis CN; Young IS; Hunter SJ; Atkinson AB; Bell PM
    J Diabetes Complications; 2014; 28(3):323-7. PubMed ID: 24560135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
    Takebayashi K; Matsumoto S; Wakabayashi S; Inukai Y; Matsutomo R; Aso Y; Inukai T
    Metabolism; 2005 Sep; 54(9):1225-9. PubMed ID: 16125534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher IGFBP3 is associated with increased incidence of colorectal cancer in older men independently of IGF1.
    Chan YX; Alfonso H; Paul Chubb SA; Ho KKY; Gerard Fegan P; Hankey GJ; Golledge J; Flicker L; Yeap BB
    Clin Endocrinol (Oxf); 2018 Feb; 88(2):333-340. PubMed ID: 29044573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
    Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of IGF1 and its binding proteins with abdominal aortic aneurysm and aortic diameter in older men.
    Yeap BB; Chubb SA; McCaul KA; Flicker L; Ho KK; Golledge J; Hankey GJ; Norman PE
    Eur J Endocrinol; 2012 Feb; 166(2):191-7. PubMed ID: 22113073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
    Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
    Stoekenbroek RM; Boekholdt SM; Fayyad R; Laskey R; Tikkanen MJ; Pedersen TR; Hovingh GK;
    Heart; 2015 Mar; 101(5):356-62. PubMed ID: 25595417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of plasma IGF1, IGFBP3 and estradiol with leucocyte telomere length, a marker of biological age, in men.
    Yeap BB; Hui J; Knuiman MW; S A Paul C; Ken K Y H; Flicker L; Divitini ML; Arscott GM; Twigg SM; Almeida OP; Hankey GJ; Golledge J; Beilby JP
    Eur J Endocrinol; 2020 Jan; 182(1):23-33. PubMed ID: 31658437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of insulin-like growth factor-I and its binding proteins and testosterone with frailty in older men.
    Yeap BB; Paul Chubb SA; Lopez D; Ho KK; Hankey GJ; Flicker L
    Clin Endocrinol (Oxf); 2013 May; 78(5):752-9. PubMed ID: 23009592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
    Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study.
    Isotton AL; Wender MC; Casagrande A; Rollin G; Czepielewski MA
    Eur J Endocrinol; 2012 Feb; 166(2):207-13. PubMed ID: 22108915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
    Harris KP; Wheeler DC; Chong CC;
    Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
    Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A
    J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle.
    Thierry van Dessel HJ; Chandrasekher Y; Yap OW; Lee PD; Hintz RL; Faessen GH; Braat DD; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1224-31. PubMed ID: 8772603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
    Gensini GF; Gori AM; Dilaghi B; Rostagno C; Gaw A; Blanco-Colio LM; de Teresa E; Egido J; Farsang C; Leiter LA; Martineau P; Nozza A; Langer A;
    Int J Cardiol; 2010 Jul; 142(3):257-64. PubMed ID: 19217176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.